These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35914117)

  • 1. The Need to Rule Out Intranasal Self-administration of Buprenorphine-Naloxone Combinations Before Prescribing Buprenorphine Without Naloxone.
    Mendelson J
    J Addict Med; 2023 Jan-Feb 01; 17(1):119. PubMed ID: 35914117
    [No Abstract]   [Full Text] [Related]  

  • 2. Is daily supervised buprenorphine-naloxone dosing necessary?
    Kleinman RA; Nielsen S; Weiss RD
    BMJ; 2022 Aug; 378():e071467. PubMed ID: 35973725
    [No Abstract]   [Full Text] [Related]  

  • 3. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 4. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 5. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 6. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.
    Resnick RB
    Ann Intern Med; 2003 Feb; 138(4):360. PubMed ID: 12585846
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of adolescent opioid dependence: no quick fix.
    Fiellin DA
    JAMA; 2008 Nov; 300(17):2057-9. PubMed ID: 18984896
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.
    Randall A; Hull I; Martin SA
    J Addict Med; 2023 Mar-Apr 01; 17(2):237-240. PubMed ID: 36149001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 10. Is buprenorphine-naloxone ready for prime time in the treatment of opioid addiction in managed care?
    Curtiss FR
    J Manag Care Pharm; 2008 Mar; 14(2):195-7. PubMed ID: 18331121
    [No Abstract]   [Full Text] [Related]  

  • 11. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
    Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
    J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine maintenance: a new treatment for opioid dependence.
    Collins GB; McAllister MS
    Cleve Clin J Med; 2007 Jul; 74(7):514-20. PubMed ID: 17682629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulfilling a Need: A Residency-Based Program to Preserve a Suboxone Treatment Program in a Rural Community.
    Buck MC; McCormick AN; Meagher MM; Kauppila G; Witt TJ
    Ann Fam Med; 2021; 19(6):561. PubMed ID: 34750133
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescription drug monitoring programs and buprenorphine maintenance: clinical considerations.
    Hoefer M; Petrakis I
    Am J Addict; 2014; 23(6):616-7. PubMed ID: 25251308
    [No Abstract]   [Full Text] [Related]  

  • 15. Buprenorphine Monoproduct for Buprenorphine/Naloxone Tolerability Problems: Navigating Stigma for Patient-centered Addiction Care without Guideline Support.
    Newcomb A
    J Addict Med; 2023 Jul-Aug 01; 17(4):493-494. PubMed ID: 37579121
    [No Abstract]   [Full Text] [Related]  

  • 16. Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals.
    Pham S; Haigh A; Barrett E
    J Addict Med; 2022 Jan-Feb 01; 16(1):e48-e51. PubMed ID: 33758118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foreword to: buprenorphine and buprenorphine/naloxone: a guide for clinicians.
    Fudala PJ; Bridge TP
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S1-2. PubMed ID: 12738345
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach.
    Vytialingam RC; Schug SA; O'Regan R
    J Opioid Manag; 2021; 17(7):159-166. PubMed ID: 34520037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.